Improving hematopoietic cell transplant outcomes in a new era of genomic research.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning.PloS one · 2019
   Article
2. Transplant genetics and genomics.Nature reviews. Genetics · 2017
   Review
3. Blood and marrow transplant clinical trials network state of the Science Symposium 2014.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015
   Article
4. Association between genetic variants in adhesion molecules and outcomes after hematopoietic cell transplants.International journal of immunogenetics · 2013
   Article
5. Genomic studies of GVHD-lessons learned thus far.Bone marrow transplantation · 2013
   Review
6. NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood--methodologic challenges.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2011
   Review
7. Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation.Current opinion in hematology · 2010
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as